Research & Educational Disclaimer
This content is for research and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making health decisions.
Type 2 diabetes is one of the most consequential and costly chronic conditions in the Australian health system. It is also, to a substantial degree, preventable. Yet prevalence has grown almost threefold over two decades, health system expenditure now exceeds $4 billion annually, and the policy response continues to lag behind both the scale of the problem and the quality of the available evidence. This article examines the epidemiology, economic burden, equity dimensions, and the policy levers — including emerging pharmacotherapy — that deserve serious attention from governments and health planners.
Prevalence: How Common Is Type 2 Diabetes in Australia?
The scale of the type 2 diabetes burden in Australia is significant and still growing. According to the Australian Institute of Health and Welfare (AIHW), almost 1.2 million Australians — approximately 4.6% of the population — were living with type 2 diabetes and registered with the National Diabetes Services Scheme (NDSS) in 2021. That figure represents a near-threefold increase from around 400,000 in the year 2000.
New diagnoses continue at a high rate. Approximately 45,700 Australians were newly diagnosed with type 2 diabetes in 2021 — around 125 people every day. When broader survey data capturing undiagnosed and self-reported cases is included, the AIHW's 2022–24 National Health Measures Survey estimates that around 1 in 15 Australians (6.5%, or approximately 1.3 million people) were living with diabetes of any type.
These numbers place Australia among the higher-burden nations in the developed world. The trajectory is not reassuring. Without meaningful structural intervention — in food environments, physical activity infrastructure, early detection, and treatment access — prevalence will continue to rise as the population ages and metabolic risk accumulates across cohorts.
Incidence Trends
A 2024 population-based study published in the Medical Journal of Australia examined changes in type 2 diabetes incidence in Australia between 2005 and 2019. The study found that while age-standardised incidence rates showed some stabilisation in certain demographic groups during this period, absolute case numbers continued to increase due to population growth and ageing. The sociodemographic gradient in incidence was striking: rates were substantially higher in lower socioeconomic groups and in rural and remote populations, compounding existing disadvantage.
Incidence data matters for policy because it reflects the current trajectory of the epidemic, not just its accumulated history. Falling incidence would signal that prevention investment is working. Stable or rising incidence signals the opposite.
Disease Burden
Beyond prevalence, the AIHW quantifies the burden of type 2 diabetes in terms of healthy life lost. In 2024, type 2 diabetes was responsible for an estimated 128,000 years of healthy life lost — accounting for 2.2% of the total burden of disease in Australia — and ranked as the 12th highest specific cause of disease burden nationally.
This burden is not uniformly distributed. It is concentrated in older age groups, in populations with lower socioeconomic status, and — disproportionately — in Aboriginal and Torres Strait Islander communities. The AIHW estimates that the rate of burden due to endocrine disorders (which includes type 2 diabetes as the dominant contributor) for Indigenous Australians is 3.6 times the rate for non-Indigenous Australians.
Type 2 diabetes also generates substantial downstream disease burden. It is a leading driver of chronic kidney disease, lower-limb amputation, diabetic retinopathy and blindness, and cardiovascular disease. Managing these complications consumes a large share of the direct cost attributed to the condition, much of it in tertiary and hospital settings rather than in the primary and preventive care that could have forestalled it.
Economic Cost to the Health System
The financial cost of type 2 diabetes to the Australian health system is large and growing. AIHW data indicates that diabetes accounted for approximately $4.4 billion — around 2.4% of total health expenditure — in 2023–24. This makes diabetes one of the highest-expenditure conditions in the health system, ahead of many cancers and musculoskeletal conditions.
A 2025 study published in Diabetes, Metabolic Syndrome and Obesity (PMID: 41124753) used linked administrative data to quantify the incremental direct costs attributable specifically to diabetes. The analysis found that average annual healthcare costs per person with diabetes (AUD 9,677) were 2.1 times higher than for people without diabetes (AUD 4,669). The total incremental cost associated with diabetes across the Australian health system was estimated at AUD 7.3 billion.
These figures encompass hospital admissions, pharmaceutical expenditure under the Pharmaceutical Benefits Scheme (PBS), primary care consultations, specialist visits, allied health, and pathology. They do not fully capture indirect costs: reduced workforce participation, absenteeism, carer burden, and early retirement due to diabetes-related disability. Comprehensive economic modelling that incorporates indirect costs places the total societal burden substantially higher — estimates in the range of AUD 14 billion annually have been cited in modelling studies.
Where the Money Goes
The distribution of health system expenditure reveals a structural problem. A disproportionate share of diabetes-related spending flows into managing established complications — hospital admissions for cardiovascular events, renal dialysis, wound management, and ophthalmology — rather than into the earlier-stage interventions that could prevent those complications from occurring. This represents a classic failure of the treatment-over-prevention funding model that has characterised Australian health policy for decades.
The preventive health funding gap in Australia is well-documented: Australia allocates approximately 1.4% of recurrent health expenditure to prevention, substantially below the OECD average and well below what the evidence base for chronic disease prevention would support. For a condition as prevention-responsive as type 2 diabetes, this imbalance has direct epidemiological and economic consequences.
Equity Dimensions
The burden of type 2 diabetes in Australia is not evenly distributed, and any serious policy analysis must account for the structural inequities that drive differential exposure and differential access to care.
First Nations Australians
The disparity in diabetes burden between Aboriginal and Torres Strait Islander peoples and non-Indigenous Australians is among the starkest health inequities in the country. Approximately 92,000 First Nations adults — 16% of the adult Indigenous population — were living with diabetes in 2022–24, according to AIHW data. First Nations adults were 3.2 times as likely as non-Indigenous adults to have diabetes, and age-standardised prevalence among First Peoples (approximately 12.6%) is roughly three times the rate in the non-Indigenous population.
This disparity is not primarily biological. It reflects decades of dispossession, disrupted food systems, socioeconomic marginalisation, inadequate housing, reduced access to culturally safe primary care, and the long-run health effects of historical policy decisions. A credible response to type 2 diabetes in First Nations communities cannot be separated from broader commitments to Closing the Gap targets, community-controlled health service funding, and addressing the social determinants of health.
Socioeconomic Gradients
Outside First Nations populations, type 2 diabetes incidence and prevalence are strongly patterned by socioeconomic position. People in the lowest socioeconomic quintile are substantially more likely to develop type 2 diabetes and more likely to experience complications — in part because of differential exposure to risk factors (food environments, sedentary work, chronic stress), and in part because of differential access to early detection and quality primary care.
The cost-sharing structures of the current health system compound this inequity. Out-of-pocket costs for GP visits, blood glucose monitoring, structured diabetes education, and allied health services are meaningful barriers for people on low incomes. Bulk-billing rates for long chronic disease consultations — the type appropriate for diabetes management — have declined. Incentive structures that reward high-volume short consultations over comprehensive care coordination work against the needs of people with complex metabolic conditions.
Rural and Remote Access
Geographic remoteness adds a further layer of inequity. People in rural and remote communities face limited access to GP services, specialist endocrinology, diabetes educators, and dietitians. Telehealth has partially mitigated this gap, but the future of telehealth as a permanent infrastructure component remains contested, and regulatory barriers continue to limit the scope of practice for non-medical health professionals who could extend the reach of diabetes care in underserved areas.
GLP-1 Receptor Agonists and the PBS Context
One of the most significant recent developments in type 2 diabetes pharmacotherapy — with direct implications for health system cost and access — is the maturation of GLP-1 receptor agonist (GLP-1 RA) therapy. Originally developed for glycaemic control in type 2 diabetes, GLP-1 RAs such as semaglutide (Ozempic) and dulaglutide (Trulicity) are currently PBS-listed for type 2 diabetes in Australia.
The clinical profile of these agents extends well beyond blood glucose reduction. GLP-1 RAs have demonstrated reductions in major adverse cardiovascular events in people with established cardiovascular disease, meaningful reductions in body weight, and — in the case of semaglutide — reductions in chronic kidney disease progression. These outcomes are directly relevant to the leading causes of premature death and hospitalisation in people with type 2 diabetes.
The PBS listing for type 2 diabetes provides subsidised access through a defined prescribing pathway, but access remains contingent on meeting eligibility criteria and navigating a primary care system under significant capacity pressure. Patients in lower socioeconomic groups, rural areas, and First Nations communities — those with the highest burden — face the greatest structural barriers to accessing these therapies even when they are nominally available on the PBS.
The broader question of PBS listing for obesity — distinct from type 2 diabetes — remains unresolved. In November 2025, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended listing semaglutide (Wegovy) for people with established cardiovascular disease and obesity, subject to pricing negotiations. As of early 2026, no PBS listing for GLP-1 RAs for weight management alone had been finalised. This matters for type 2 diabetes prevention: obesity is the single largest modifiable risk factor for developing type 2 diabetes, and population-level access to effective weight management pharmacotherapy could, in principle, substantially reduce future incidence.
This question is examined in depth in the Medicare and PBS obesity treatment reform analysis, which covers the PBAC process, cost-effectiveness thresholds, and equity implications of subsidy decisions.
The Case for Metabolic Intervention and Prevention Funding
The evidence that type 2 diabetes is substantially preventable — and that prevention is cost-effective — is extensive and well-established. Landmark trials including the Diabetes Prevention Program (United States) and the Finnish Diabetes Prevention Study demonstrated that structured lifestyle intervention in people with prediabetes can reduce progression to type 2 diabetes by 58%. These trials were conducted in the 1990s and early 2000s. The evidence has only strengthened since.
Prevention investment delivers returns across multiple time horizons. In the short term, structured diabetes prevention programs reduce the incidence of new diagnoses, freeing primary care and specialist capacity. In the medium term, they reduce the incidence of costly complications — cardiovascular events, renal failure, amputation. In the long term, they reduce the structural burden on a health system that is already spending disproportionately on late-stage disease management.
Australia has had a National Diabetes Strategy since 2016. The current iteration — the National Diabetes Strategy 2021–2030 — articulates ambitions for prevention, early detection, and equitable access to evidence-based care. The gap between strategic aspiration and funded implementation is, however, substantial. Prevention programs at scale require recurrent funding commitments across electoral cycles, accountability mechanisms for outcomes, and integration with the primary care and public health infrastructure through which most Australians interact with the health system.
Primary Care as a Prevention Platform
General practice is the logical site for type 2 diabetes prevention at population scale. The GP encounter offers a recurring, trusted relationship in which risk factor assessment, lifestyle counselling, and referral to structured prevention programs can be embedded. The current Medicare incentive structure, however, does not adequately reward this work. Short consultation items dominate billing patterns. GP Management Plans and Team Care Arrangements — the formal mechanisms for chronic disease care — are under-utilised in prevention contexts because the administrative burden is high and the reimbursement modest.
Reform proposals that would better align Medicare incentives with prevention and early intervention for metabolic disease have circulated in policy discussions for years. The obesity crisis in Australia — which shares its epidemiology and risk factor profile substantially with type 2 diabetes — illustrates why incentive reform cannot be indefinitely deferred: the clinical and economic consequences of inaction compound over time.
Structural investment in the metabolic syndrome policy gap — which encompasses insulin resistance, impaired glucose tolerance, and pre-diabetes as well as established type 2 diabetes — offers the most upstream opportunity for prevention. Addressing the metabolic syndrome cluster before progression to type 2 diabetes is both clinically and economically preferable to managing complications after the fact.
Policy Recommendations
A coherent policy response to the type 2 diabetes burden in Australia would encompass several interlocking elements:
Prevention investment at scale. Recurrent Commonwealth funding for structured diabetes prevention programs — modelled on the evidence base from the Diabetes Prevention Program and its international adaptations — delivered through Primary Health Networks and targeted at high-risk populations, including those with prediabetes, obesity, and First Nations Australians.
Medicare incentive reform. Revision of GP consultation item numbers and chronic disease management items to better reward time-intensive metabolic risk assessment, prevention counselling, and care coordination, rather than creating a financial incentive for high-volume short encounters.
PBS access equity. Active monitoring of prescribing and dispensing patterns for PBS-listed GLP-1 RAs to ensure that access is not concentrated in higher socioeconomic groups. Specific access pathways for First Nations Australians and remote populations, consistent with existing PBS Closing the Gap measures.
Community-controlled health services. Sustained and increased funding for Aboriginal Community Controlled Health Organisations (ACCHOs), which deliver culturally appropriate primary care and chronic disease management to First Nations populations. The evidence that community-controlled services deliver better diabetes outcomes than mainstream services for this population is strong.
Data and accountability. Improved linkage between NDSS registration data, PBS dispensing data, and hospital admissions data to enable outcome monitoring at population and subgroup level. Publication of prevention program outcomes under the National Diabetes Strategy framework with clear accountability to stated targets.
Conclusion
Type 2 diabetes represents one of the most significant and tractable challenges in Australian health policy. The epidemiology is clear: 1.2 million Australians diagnosed, 125 new cases daily, $4.4 billion in direct health system expenditure, and a burden that falls disproportionately on those least able to absorb it. The evidence base for prevention, early intervention, and equitable access to pharmacotherapy is robust. The gap between that evidence base and the funded, implemented policy response is wide.
The conversation in Australia has too often been captured by the downstream pharmacotherapy debate — which medicines the PBS should list, and at what cost — while the upstream prevention infrastructure that could reduce future incidence remains chronically underfunded. Both dimensions matter. A health system serious about type 2 diabetes must invest simultaneously in preventing new cases and in ensuring that those living with the condition have equitable access to evidence-based treatment, wherever they live and regardless of their income.
Sources and further reading:
- Australian Institute of Health and Welfare. Diabetes: Australian facts — Type 2 diabetes. https://www.aihw.gov.au/reports/diabetes/diabetes/contents/how-common-is-diabetes/type-2-diabetes
- Australian Institute of Health and Welfare. Diabetes: Australian facts — Health system expenditure. https://www.aihw.gov.au/reports/diabetes/diabetes/contents/impact-of-diabetes/health-system-expenditure
- Asiamah-Asare BKY, Randall S, Mnatzaganian G, et al. The economic impact of diabetes: Assessing incremental direct costs in Australia using linked administrative data. Diabetes, Metabolic Syndrome and Obesity, 2025. PubMed PMID: 41124753. https://pubmed.ncbi.nlm.nih.gov/41124753/